OPKO Health 2025 Q3 Earnings Misses Revenue Estimates, EPS Beats as Strategic Collaborations Drive Growth

OPKO Health (OPK) reported mixed third-quarter 2025 results, with revenue falling short of estimates but EPS exceeding expectations. The company’s strategic moves, including a $225M asset sale and a $1B+ partnership with Regeneron, highlighted its pivot toward long-term growth and operational efficiency.

Revenue

Pharmaceutical revenue totaled $56.42 million, while the Diagnostics segment contributed $95.24 million. The Corporate segment reported no revenue, resulting in a total of $151.67 million for the quarter, a 12.6% decline year-over-year. This followed the sale of BioReference oncology assets, which shifted the revenue mix toward core diagnostics and therapeutics.

Earnings/Net Income

Earnings per share (EPS) declined 25% to $0.03, while net income dropped 13.1% to $21.63 million. Despite the EPS decline, the net income decrease was relatively modest, supported by cost-cutting measures and a $101.6M gain from the asset sale.

Post-Earnings Price Action Review

OPKO Health’s stock surged 5% post-earnings, buoyed by the EPS beat and optimism around its Regeneron collaboration. However, the stock fell 7.1% month-to-date, underperforming the S&P 500’s +3.8%. Analysts remain bullish, with a Zacks Rank #2 (Buy), citing long-term catalysts like the Merck EBV vaccine trial and ModeX’s multispecific antibody programs.

CEO Commentary

CEO Phillip Frost emphasized progress in strategic partnerships, including the Regeneron collaboration and the BioReference asset sale, which funded share repurchases. He highlighted operational improvements, with Q3 operating income at $48.1M, and ongoing R&D advancements in diagnostics and therapeutics.

Guidance

OPKO did not provide specific revenue or EPS targets for 2025 but outlined continued investment in ModeX’s antibody platforms and clinical trials. The company plans to use asset sale proceeds for share repurchases under its $200M buyback program.

Additional News

OPKO’s $225M sale of BioReference oncology assets to Labcorp and a $1B+ research partnership with Regeneron underscored its focus on high-impact collaborations. The company also announced $73.8M in share repurchases under its 2024 buyback program. ModeX’s MDX2004 trial initiation and Merck’s EBV vaccine progress further solidified its pipeline’s potential.

<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-aime_generated_1761861245611.jpg.png" style="max-width:100%;">